The RSI Indicator for CYTK moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 22 of the 24 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 69 cases where CYTK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for CYTK just turned positive on October 13, 2026. Looking at past instances where CYTK's MACD turned positive, the stock continued to rise in 41 of 57 cases over the following month. The odds of a continued upward trend are 72%.
Following a +3.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where CYTK advanced for three days, in 216 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
CYTK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on September 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CYTK as a result. In 83 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYTK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for CYTK entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. CYTK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 73 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYTK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (60.606) is normal, around the industry mean (26.782). CYTK's P/E Ratio (702.500) is considerably higher than the industry average of (43.395). CYTK's Projected Growth (PEG Ratio) (82.230) is slightly higher than the industry average of (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (128.205) is also within normal values, averaging (437.542).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
OTLK saw its Momentum Indicator move below the 0 level on September 24, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned negative. In 82 of the 93 cases, the stock moved further down in the following days. The odds of a decline are at 88%.
The Moving Average Convergence Divergence Histogram (MACD) for OTLK turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 35 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OTLK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where OTLK's RSI Indicator exited the oversold zone, 25 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +3.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where OTLK advanced for three days, in 195 of 239 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
OTLK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 122 of 153 cases where OTLK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
The Tickeron Seasonality Score of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. OTLK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (39.216) is normal, around the industry mean (26.782). P/E Ratio (0.594) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (128.205) is also within normal values, averaging (437.542).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OTLK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CYTK | OTLK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 76 | 3 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 100 Overvalued | 77 Overvalued | |
PROFIT vs RISK RATING 1..100 | 73 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 62 | 65 | |
P/E GROWTH RATING 1..100 | 1 | 14 | |
SEASONALITY SCORE 1..100 | 50 | 10 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
OTLK's Valuation (77) in the Biotechnology industry is in the same range as CYTK (100). This means that OTLK’s stock grew similarly to CYTK’s over the last 12 months.
CYTK's Profit vs Risk Rating (73) in the Biotechnology industry is in the same range as OTLK (100). This means that CYTK’s stock grew similarly to OTLK’s over the last 12 months.
CYTK's SMR Rating (100) in the Biotechnology industry is in the same range as OTLK (100). This means that CYTK’s stock grew similarly to OTLK’s over the last 12 months.
CYTK's Price Growth Rating (62) in the Biotechnology industry is in the same range as OTLK (65). This means that CYTK’s stock grew similarly to OTLK’s over the last 12 months.
CYTK's P/E Growth Rating (1) in the Biotechnology industry is in the same range as OTLK (14). This means that CYTK’s stock grew similarly to OTLK’s over the last 12 months.
| CYTK | OTLK | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 89% |
| Stochastic ODDS (%) | 1 day ago 70% | 1 day ago 89% |
| Momentum ODDS (%) | 1 day ago 85% | 1 day ago 88% |
| MACD ODDS (%) | 1 day ago 72% | 1 day ago 81% |
| TrendWeek ODDS (%) | 1 day ago 71% | 1 day ago 85% |
| TrendMonth ODDS (%) | 1 day ago 76% | 1 day ago 84% |
| Advances ODDS (%) | 1 day ago 73% | 12 days ago 82% |
| Declines ODDS (%) | 4 days ago 78% | 3 days ago 84% |
| BollingerBands ODDS (%) | 1 day ago 64% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 85% | 1 day ago 80% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CYTK’s FA Score shows that 1 FA rating(s) are green while OTLK’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CYTK’s TA Score shows that 5 TA indicator(s) are bullish while OTLK’s TA Score has 5 bullish TA indicator(s).
CYTK (@Biotechnology) experienced а +3.08% price change this week, while OTLK (@Biotechnology) price change was -11.35% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.32%. For the same industry, the average monthly price growth was -15.10%, and the average quarterly price growth was -18.48%.
CYTK is expected to report earnings on Oct 29, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| JPRE | 50.18 | 0.38 | +0.76% |
| JPMorgan Realty Income ETF (JPRE) | |||
| EFRA | 34.79 | 0.14 | +0.42% |
| iShares Environmental Infrastructure and Industrials ETF (EFRA) | |||
| BCGS | 25.80 | 0.05 | +0.19% |
| Bancreek Global Select ETF (BCGS) | |||
| OAEM | 47.52 | -0.05 | -0.10% |
| OneAscent Enhanced Small and Mid Cap ETF Institutional Shs OneAscent Emerging Markets Fund (OAEM) | |||
| PWB | 156.36 | -0.95 | -0.60% |
| Invesco Large Cap Growth ETF (PWB) | |||
A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with DARE. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then DARE could also see price increases.
| Ticker / NAME | Correlation To CYTK | 1D Price Change % | ||
|---|---|---|---|---|
| CYTK | 100% | +0.77% | ||
| DARE - CYTK | 42% Loosely correlated | +1.51% | ||
| AXSM - CYTK | 41% Loosely correlated | -0.27% | ||
| BBIO - CYTK | 41% Loosely correlated | +3.37% | ||
| VRDN - CYTK | 40% Loosely correlated | +6.42% | ||
| CVM - CYTK | 39% Loosely correlated | +1.75% | ||
More | ||||
A.I.dvisor indicates that over the last year, OTLK has been loosely correlated with APVO. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if OTLK jumps, then APVO could also see price increases.
| Ticker / NAME | Correlation To OTLK | 1D Price Change % | ||
|---|---|---|---|---|
| OTLK | 100% | +6.34% | ||
| APVO - OTLK | 45% Loosely correlated | -1.73% | ||
| ICU - OTLK | 36% Loosely correlated | +1.66% | ||
| GNPX - OTLK | 34% Loosely correlated | -1.72% | ||
| CYTK - OTLK | 33% Loosely correlated | +0.77% | ||
| PDSB - OTLK | 33% Loosely correlated | -7.80% | ||
More | ||||